{"filings":[{"id":141285,"accession_number":"0001104659-25-071716","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"HOOKIPA shareholders approve asset sale to Gilead and company dissolution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Asset sale to Gilead Sciences approved: 5,063,462 for, 239,595 against, 1,502 abstain.","Plan of liquidation and dissolution approved: 4,969,875 for, 329,803 against, 4,881 abstain.","Adjournment proposal approved: 5,110,153 for, 191,383 against, 3,023 abstain.","Special meeting held July 29, 2025; 54.13% of outstanding shares voted.","Company will proceed with dissolution following asset sale closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141284,"accession_number":"0001104659-25-069029","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA plans voluntary delisting and deregistration ahead of asset sale to Gilead and dissolution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Intends to voluntarily delist from Nasdaq; Form 25 expected July 29, delisting effective ~August 8, 2025.","Will file Form 15 to deregister under Section 12(g) and suspend SEC reporting after delisting.","Delisting/deregistration tied to pending asset sale to Gilead for HB-400/HB-500 programs and planned dissolution.","Special meeting of stockholders set for July 29, 2025 to approve asset sale and dissolution.","Upon dissolution, proceeds from asset sale and other assets to be distributed to stockholders after liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159097,"accession_number":"0001104659-25-051841","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","1.02","5.02","8.01","9.01"],"status":"ready","headline":"HOOKIPA to sell HB-400/HB-500 assets to Gilead for up to $10M; board approves dissolution","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gilead to acquire HB-400 and HB-500 assets for up to $10M in cash; $3M at closing, up to $7M in transfer completion payments.","Board approved dissolution of HOOKIPA; filing of Certificate of Dissolution expected after Transfer Plan completion.","Asset sale and dissolution require stockholder approval; proxy statement to be filed for special meeting.","CEO Malte Peters receives severance, accelerated equity vesting, and a Special Dissolution Success Bonus up to €482,591.","Collaboration Agreement and Stock Purchase Agreement with Gilead will terminate at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177546,"accession_number":"0001104659-25-015647","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA abandons plan to acquire Poolbeg Pharma; issues Rule 2.8 no-offer statement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HOOKIPA board decides not to proceed with all-share acquisition of Poolbeg Pharma announced on Jan 2, 2025.","Announcement made under UK Takeover Code Rule 2.8; HOOKIPA reserves right to reverse under certain conditions.","Discussions for combination have ceased; no firm offer was made.","Financial adviser Moelis & Company advised HOOKIPA on the potential deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177545,"accession_number":"0001104659-25-007015","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"HOOKIPA files Section 205 petition to validate 2022/2023 stockholder actions due to record date errors; hearing Feb 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date for 2022 annual meeting was 78 days before the meeting (April 13 vs. June 30, 2022), violating DGCL 60-day limit.","Record date for 2023 annual meeting was 66 days before the meeting (April 4 vs. June 9, 2023), also noncompliant.","Petition seeks validation of 2022 share increase (100M to 200M shares), plan amendment, and director elections from both meetings.","As of April 2024, over 36.6M shares may be invalid if 2022 amendment is not validated, affecting subsequent corporate actions.","Delaware Chancery Court will hold final hearing on Feb 14, 2025; stockholders may appear or submit written positions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177544,"accession_number":"0001104659-25-002517","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA and Poolbeg update: Gilead to invest up to $8.75M in potential combination fundraise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gilead intends to vote consistent with HOOKIPA board recommendation if a formal offer is made.","Gilead to participate in concurrent Fundraise up to $8.7495 million, consistent with existing obligations.","Discussions remain non-binding and non-exclusive; no assurance of a firm offer or transaction completion.","Update follows prior announcements on January 2 and January 7, 2025 regarding the potential combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177543,"accession_number":"0001104659-25-001553","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA reports Gilead support for potential Poolbeg acquisition; fundraise revised to $30M+ primary placement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gilead, owning 19.4% of HOOKIPA shares, signals intent to vote for the deal and join the $30M+ fundraise.","HOOKIPA revised fundraise to ~$30M+ primary private placement (previously up to ~$30M).","Oppenheimer & Co. Inc. engaged as placement agent for the private placement fundraise.","Discussions remain non-binding; no assurance a firm offer will be made or deal completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177542,"accession_number":"0001104659-25-000020","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA announces non-binding discussions to acquire Poolbeg Pharma in all-share deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Poolbeg shareholders to receive 0.03 HOOKIPA shares per share; expected ~55% ownership of combined entity before planned $30M fundraise.","Combined group to be Nasdaq-listed with operations in EU, UK, and US; Poolbeg to delist from AIM.","CVR for HOOKIPA shareholders tied to Gilead milestones (up to $407.5M) and HB-200 proceeds.","PUSU deadline under UK Takeover Code set for 30 January 2025; no certainty a firm offer will be made.","Fundraise of up to $30M to extend cash runway through year-end 2026, concurrent with deal completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194261,"accession_number":"0001104659-24-121019","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HOOKIPA cuts workforce ~80%, pauses eseba-vec HPV16+ trial, focuses on HB-700","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~80%; implementation begins Q4 2024, substantially complete by H1 2025.","Pauses eseba-vec program; early termination of Phase 1/2 trial for HPV16+ head and neck cancers (not due to safety or efficacy).","Focuses on phase 1-ready HB-700 for KRAS mutated cancers (lung, colorectal, pancreatic); FDA IND clearance received Apr 2024.","Continues HB-500 (HIV) Phase 1b trial and HB-400 (Hepatitis B) program with partner Gilead.","Will seek partnering opportunities for the eseba-vec program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194260,"accession_number":"0001558370-24-015708","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.","Cash $60.0M at Sep 30, 2024 (from $117.5M Dec 2023); received $5M milestone from Gilead for HB-500 dosing.","Phase 2 eseba-vec + pembrolizumab in HPV+ HNSCC enrolled 68 patients ahead of schedule; updated data at SITC 2024.","First patients dosed in MSKCC Investigator Initiated Trial of eseba-vec as adjuvant therapy for HNSCC.","Leadership: Malte Peters appointed CEO, Terry Coelho CFO in July; reverse stock split effected 1:10."],"consensus_eps_estimate":-1.3036,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":42592000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210588,"accession_number":"0001104659-24-095236","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HOOKIPA Pharma: two directors resign; Julie O'Neill appointed Non-Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jan van de Winkel and Tim Reilly resign effective Aug 30, 2024, citing increased time commitments from other roles.","Julie O'Neill appointed Non-Executive Chair; Board reduced from 6 to 5 members.","Board reclassified into three classes; O'Neill reappointed as Class I director, term expiring at 2026 Annual Meeting.","Audit Committee: Cassidy (Chair), Kaufman, O'Neill; Compensation: O'Neill (Chair), Cassidy; Nominating: Kaufman (Chair), Cassidy.","Resignations not due to any disagreement with Company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210587,"accession_number":"0001558370-24-011626","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.","Cash, cash equivalents and restricted cash fell to $77.4M from $117.5M as of Dec 31, 2023.","Malte Peters appointed CEO and Terry Coelho as EVP & CFO effective July 22, 2024.","Eseba-vec (HB-200) AVALON-1 Phase 2/3 trial aligned with FDA; start expected Q4 2024.","Received $5M milestone from Gilead for HB-500 HIV Phase 1b first dosing; $10M from Roche for HB-700 IND."],"consensus_eps_estimate":-1.2776,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":37889000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210586,"accession_number":"0001104659-24-083019","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.02","7.01","1.01","9.01"],"status":"ready","headline":"HOOKIPA Pharma appoints Dr. Malte Peters CEO and Terry Coelho CFO; launches strategic review for HB-200","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Malte Peters appointed CEO & President effective July 22, 2024; salary $630k, RSU award $700k.","Terry Coelho appointed EVP & CFO effective July 22, 2024; salary $480k, signing bonus $240k, RSU $450k.","Former CEO Jörn Aldag and CFO Reinhard Kandera separated July 22, resigned from board July 23.","Sean Cassidy appointed independent director and Audit Committee chair effective July 22.","Company launches strategic review to focus on HB-200 and create shareholder value; no impact on operations or trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210585,"accession_number":"0001104659-24-078760","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"HOOKIPA Pharma completes 1-for-10 reverse stock split, effective July 9, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-10 reverse split effective 5:00 p.m. ET on July 9, 2024; par value unchanged at $0.0001.","Authorized shares reduced from 400M to 40M; fractional shares cashed out.","Outstanding shares reduced from ~96.6M to ~9.7M immediately after split.","Conversion ratios/exercise prices adjusted for convertible preferred stock, stock options, and equity plans.","Reverse split was previously disclosed and affects all stockholders uniformly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228925,"accession_number":"0001104659-24-072792","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"HOOKIPA shareholders approve doubling authorized shares and authorize reverse split","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock increased from 200M to 400M shares; approved by 64.8M for, 3.4M against.","Shareholders authorized board to implement reverse stock split (1:2 to 1:10) before June 17, 2025; 63.4M for, 4.7M against.","Directors Timothy Reilly and Malte Peters elected to Class II with 51.9M and 53.9M votes respectively.","Ratification of PwC Wirtschaftsprüfung GmbH as independent auditor for FY2024 approved (67.6M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228924,"accession_number":"0001104659-24-068248","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA reports 53% ORR in CPS≥20 subgroup from Phase2 HB-200 + pembro trial at ASCO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Among 35 evaluable first-line HPV16+ HNSCC patients, ORR 37%, CR 11%, DCR 69% per RECIST 1.1.","In CPS≥20 subgroup (N=17, registrational target): ORR 53%, CR 18%, DCR 82%; PFS 16.3 mo, OS rate 88% at 9 mo.","HB-200 + pembrolizumab well-tolerated; Grade≥3 TRAEs in 15%, no treatment-related deaths.","Company plans to begin pivotal Phase 2/3 trial in Q4 2024 with FDA alignment on path to accelerated approval.","Data presented as oral abstract at ASCO 2024; median follow-up for CPS≥20 subgroup was 8.4 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228923,"accession_number":"0001104659-24-064762","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.","Median follow-up 5.6 months; grade ≥3 TRAEs in 14% of patients, no treatment-related deaths.","Neoadjuvant HB-200 + chemo showed deep responses in 81% (17/21) of HPV16+ oropharyngeal cancer patients.","HB-700 preclinical data induced KRAS mutation-specific T cell responses; Phase I planned for KRAS-mutated cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228922,"accession_number":"0001558370-24-007462","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.","Net income $14.4M vs net loss $19.7M in Q1 2023; cash $93.0M as of March 31, 2024.","HB-200 Phase 2/3 pivotal trial design aligned with FDA; first patient enrollment expected Q4 2024; PRIME designation from EMA.","HB-700 IND cleared for KRAS-mutated cancers; received $10M milestone from Roche; regained full IP control.","Mark Winderlich appointed Chief Development Officer effective April 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":36599000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228921,"accession_number":"0001104659-24-051581","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"HOOKIPA announces pivotal Phase 2/3 trial design for HB-200 in combo with pembrolizumab; FDA alignment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pivotal Phase 2/3 trial for HB-200 + pembrolizumab in first-line HPV16+ recurrent/metastatic OPSCC; FDA alignment achieved.","Trial expected to enroll ~250 patients; Phase 2 primary analysis in 2026 with potential accelerated approval filing.","First patient enrollment anticipated in Q4 2024.","HB-200 abstract accepted as oral presentation at ASCO 2024 with data from ~40 patients in head and neck cancer.","Company also received PRIME designation from EMA for HB-200 in combination with pembrolizumab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247560,"accession_number":"0001558370-24-003735","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.","Revenue $7.4M (Q4) and $20.1M (FY2023); R&D expenses $21.2M and $86.4M.","Cash and equivalents $117.5M at Dec 31, 2023, including $71M from capital raises and $15M in milestones.","HB-200 + pembrolizumab showed 42% objective response rate in 1L HPV16+ HNSCC; pivotal trial to start 2024.","Roche terminated HB-700 collaboration; HOOKIPA to regain rights; IND filing by April 2024 triggers final milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}